Peer-Reviewed Publications

    Development of an Adverse Outcome Pathway for the onset of hypertension by oxidative stress-mediated perturbation of endothelial nitric oxide bioavailability

    Lowe, F. J.; Luettich, K.; Talikka, M.; Hoang, V.; Haswell, L. E.; Hoeng, J.; Gaca, M. D.
    Published
    Mar 1, 2017
    DOI
    10.1089/aivt.2016.0031
    Link to publication
    Topic
    Summary

    Hypertension is a cardiovascular risk factor that has a profound influence on cardiovascular morbidity and mortality. While good progress has been made in terms of identifying and managing this risk factor for patient care, methods to assess the potential of chemical compounds to induce hypertension or to assess the efficacy of consumer products (e.g., e-cigarettes) targeted at reducing disease burden remain largely limited to epidemiological associations and in vivo studies. The field of toxicology has undergone a paradigm shift toward the replacement of in vivo testing in toxicological risk assessment. The adverse outcome pathway (AOP) framework could facilitate improved knowledge-based risk/benefit assessment of chemicals or consumer products, respectively, without the necessity of animal testing. Furthermore, to facilitate a more timely, cost effective, and ethical solution for risk/efficacy assessment purposes, integrated testing strategies are required, which do not heavily rely on in vivo studies. In this study, we present the supporting information on an AOP describing how vascular endothelial peptide oxidation leads to hypertension through perturbation of endothelial nitric oxide bioavailability, leading to impaired vasodilation. We also discuss the essentiality of the key events (KEs), and biological plausibility and empirical support of KE relationships, in accordance with the Organisation for Economic Cooperation and Development (OECD) handbook. This AOP could be a useful tool to serve as a foundation for a future integrated testing strategy for the regulatory assessment of the harm reduction potential of e-cigarettes relative to conventional tobacco products and other consumer products, which aim to reduce cardiovascular disease risk.

    Related Publications

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition: Biological Network Models

    Systems Toxicology

    Verification of systems biology research in the age of collaborative competition

    Systems Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative - Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition: Biological Network Models

    Systems Toxicology

    Verification of systems biology research in the age of collaborative competition

    Systems Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative - Competition

    Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.